Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-25-006996
Filing Date
2025-05-08
Accepted
2025-05-08 16:31:19
Documents
66
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q xlo-20250331x10q.htm   iXBRL 10-Q 1655412
2 EX-10.1 xlo-20250331xex10d1.htm EX-10.1 935454
3 EX-10.2 xlo-20250331xex10d2.htm EX-10.2 184655
4 EX-10.3 xlo-20250331xex10d3.htm EX-10.3 133994
5 EX-31.1 xlo-20250331xex31d1.htm EX-31.1 13263
6 EX-31.2 xlo-20250331xex31d2.htm EX-31.2 13166
7 EX-32.1 xlo-20250331xex32d1.htm EX-32.1 7773
  Complete submission text file 0001558370-25-006996.txt   7299099

Data Files

Seq Description Document Type Size
8 EX-101.SCH xlo-20250331.xsd EX-101.SCH 46144
9 EX-101.CAL xlo-20250331_cal.xml EX-101.CAL 33738
10 EX-101.DEF xlo-20250331_def.xml EX-101.DEF 212407
11 EX-101.LAB xlo-20250331_lab.xml EX-101.LAB 373292
12 EX-101.PRE xlo-20250331_pre.xml EX-101.PRE 324408
69 EXTRACTED XBRL INSTANCE DOCUMENT xlo-20250331x10q_htm.xml XML 651457
Mailing Address 828 WINTER STREET WALTHAM MA 02451
Business Address 828 WINTER STREET WALTHAM MA 02451 617-833-1027
Xilio Therapeutics, Inc. (Filer) CIK: 0001840233 (see all company filings)

EIN.: 851623397 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40925 | Film No.: 25926820
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)